Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 2INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Small Cell Lung Carcinoma 2Melanoma 1Lymphoma, Mantle-Cell 1Lymphoma, Follicular 1Lung Neoplasms 1Leukemia, Myeloid, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hodgkin Disease 1Hematologic Neoplasms 1

Interventions

Rituximab 30ibrutinib 26Bendamustine Hydrochloride 18Cyclophosphamide 17acalabrutinib 14fludarabine 13Lenalidomide 11zanubrutinib 10venetoclax 9Vincristine 7Bortezomib 7pirtobrutinib 5brexucabtagene autoleucel 5Prednisone 5Doxorubicin 5temsirolimus 4parsaclisib 4aflibercept 4Gemcitabine 4ublituximab 3orelabrutinib 3loncastuximab tesirine 3idelalisib 3ibritumomab tiuxetan 3Sensitivity and Specificity 3Antigens, CD19 3tositumomab I-131 2tazemetostat 2pembrolizumab 2fludarabine phosphate 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Lymphoma, Mantle-Cell × obatoclax × Clear all
NCT00407303 2016-07-21

Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) in Combination With Bortezomib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma (MCL)

Teva Branded Pharmaceutical Products R&D, Inc.

Phase 1/2 Completed
24 enrolled
Lymphoid

Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡